FIRMM

FIRMM, operating under the brand Turing Medical, is a neuromodulation technology company focused on precision brain mapping and adaptive cortical stimulation.

Reviewed by 7wData
Share Email

On this page

Profile

Develops non-invasive brain stimulation therapies for conditions like depression and chronic pain.

FIRMM, operating under the brand Turing Medical, is a neuromodulation technology company focused on precision brain mapping and adaptive cortical stimulation. Founded by neuroscientists Nico Dosenbach and Damien Fair, the company emerged from academic research into brain plasticity and functional mapping, notably publishing a landmark study on psilocybin's effects on brain plasticity in Nature in August 2024. In April 2025, Turing Medical appointed Kevin King, a seasoned med-tech executive with three decades of experience in precision medicine, as its new President and CEO to drive commercialization.

The company's flagship product, PACE (Precision Guided Neuromodulation Therapy), combines functional brain mapping with adaptive cortical stimulation to treat severe depression and chronic pain, positioning itself as a non-invasive alternative to deep brain surgery. While financial specifics are undisclosed, the leadership transition and academic pedigree suggest a pivot toward clinical and commercial scaling. The neuromodulation market, valued at $6.5 billion in 2024 (Grand View Research), is crowded with deep-brain stimulation incumbents like Medtronic and Abbott, but FIRMM's focus on non-invasive precision targeting differentiates its approach.

Track FIRMM and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Hospitals and neurology departments
  • Psychiatric treatment centers
  • Chronic pain management clinics
  • Research institutions studying neuromodulation
  • Neuroscience-focused biotech partners

Strengths and what to watch

Strengths

  • Academic co-founders with published research in top-tier journals like Nature
  • Non-invasive approach contrasts with surgical deep-brain stimulation alternatives
  • Experienced med-tech leadership under CEO Kevin King

Watch for

  • Unproven clinical efficacy—PACE lacks published trial results versus established treatments
  • High R&D costs in neuromodulation with long regulatory pathways
  • Leadership transition risks as new CEO scales commercialization

Key Information

Founded
1848
Headquarters
United States

Frequently Asked Questions

What is FIRMM?

FIRMM, operating as Turing Medical, is a neuromodulation technology company specializing in non-invasive brain stimulation therapies. It focuses on precision brain mapping and adaptive cortical stimulation to treat conditions like depression and chronic pain, offering an alternative to surgical deep-brain stimulation.

How does FIRMM's technology work?

FIRMM's flagship product, PACE, combines functional brain mapping with adaptive cortical stimulation. This non-invasive approach targets specific brain regions to treat severe depression and chronic pain, avoiding the need for deep-brain surgery while leveraging precision-guided neuromodulation therapy.

Who leads FIRMM?

FIRMM is led by CEO Kevin King, a seasoned med-tech executive with three decades of experience in precision medicine. Co-founders Nico Dosenbach and Damien Fair, neuroscientists, bring academic expertise in brain plasticity and functional mapping, driving the company's research and innovation.

What conditions does FIRMM treat?

FIRMM's neuromodulation therapies target severe depression and chronic pain. Its non-invasive approach, using precision-guided brain mapping and adaptive cortical stimulation, provides an alternative to traditional deep-brain surgery, catering to hospitals, psychiatric centers, and pain management clinics.

How is FIRMM different from competitors?

FIRMM differentiates itself with its non-invasive precision targeting, contrasting with surgical deep-brain stimulation alternatives from incumbents like Medtronic and Abbott. Its focus on adaptive cortical stimulation and academic research underpins its innovative approach to neuromodulation therapy.

What are the challenges FIRMM faces?

FIRMM faces challenges such as unproven clinical efficacy for PACE, high R&D costs, and long regulatory pathways in neuromodulation. Leadership transition risks also exist as the company scales commercialization under new CEO Kevin King, balancing innovation with market expansion.

Sources

  1. turingmedical.com — CEO appointment and company focus
  2. turingmedical.com — Academic co-founders' research background
  3. turingmedical.com — Product description and positioning
  4. turingmedical.com — Company overview and product branding